Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Classificação em ações #6354
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Preço da ação
$33.00
Valor de mercado
$2.08B
Variação (1 dia)
-0.12%
Variação (1 ano)
97.49%
País
US
Negociar Zenas BioPharma, Inc. (ZBIO)

Categoria

Histórico de rendimento de dividendos para Zenas BioPharma, Inc. (ZBIO)
O rendimento de dividendos (TTM) da Zenas BioPharma, Inc. (símbolo da ação: ZBIO) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Zenas BioPharma, Inc. (ZBIO) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
Não há dados suficientes para as datas fornecidas.
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH